Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents

European Journal of Vascular and Endovascular Surgery

Volumn 26, Issue 4, 2003, Pages 374-380

  Fiotti, N ^a   Altamura, N ^a   Cappelli, C ^a   Schillan, M ^a   Guarnieri, G ^a   Giansante, C ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTITHROMBOCYTIC AGENT; PARACETAMOL; TICLOPIDINE;

ADULT; AGE; AGED; ARTERY DISEASE; ARTICLE; BLOOD VESSEL INJURY; CANCER; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CAUSE OF DEATH; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FATALITY; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIA; LEG AMPUTATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STROKE; TREATMENT OUTCOME;

EID: 0142091633     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5884(03)00318-6     Document Type: Article

References (24)

1. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery F, Bousser MG, Clement D, Coffman J, Deutshinoff A. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989; 30: 50-57.
2. Dormandy JA, Mahir MS. The natural history of peripheral atheromatous disease of legs. In: Greenhalg RM, Jamieson CW, Nicolaides AN, eds. Vascular Surgery Issues in Current Practice. London: Grune and Stratton, Ltd, 1986: 3-17.
3. Management of Peripheral Arterial Disease (PAD), TransAtlantic Inter-Society Consensus (TASC). Int Angiol 2000; 19(Suppl. 1): I-XXIV. see also 1-304.
4. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevat J, Weinstein MC. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-542.
5. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990; 322: 1635-1641.
6. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81: 380-386.
7. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96: 44-49.
8. Schmieder FA, Comerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001; 87: 3D-13D.
9. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002; 324: 71-86.
10. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 2002; 112: 49-57.
11. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002; 3: 461-469.
12. Chen MJ, Chiou YY, Wu DC, Wu SL. Lifestyle habits and gastric cancer in a hospital-based case-control study in Taiwan. Am J Gastroenterol 2000; 95: 3242-3249.
13. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001; 84: 965-968.
14. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow. Russia Int J Cancer 1999; 82: 473-476.
15. Newberne PM, Charnley G, Adams K, Cantor M, Suphakarn V, Roth D, Schrager TF. Gastric carcinogenesis: a model for the identification of risk factors. Cancer Lett 1987; 38: 149-163.
16. Cohen A, Geller SA, Horowitz I, Toth LS, Werther JL. Experimental models for gastric leiomyosarcoma. The effects of N-methyl-N′-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate. Cancer 1984; 53: 1088-1092.
17. Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B, Leppert M. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 1079-1084.
18. Slattery ML, Curtin K, Anderson K, Ma KN, Ballard L, Edwards S, Schaffer D, Potter J, Leppert M, Samowitz WS. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000; 92: 1831-1836.
19. Arber N, DuBois RN. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep 1999; 1: 441-448.
20. CAPRIE Steering Committee, A randomised blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-1339.
21. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
22. Michaels L, Galbraith PA, Ledwich JR. Proceedings: a clinical trial of antiplatelet therapy in patients with coronary arterial disease. Thromb Diath Haemorrh 1975; 34: 598-599.
23. Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol 1982; 35: 740-743.
24. Carrieri P, Orefice G, Fioretti A, Indaco A, Carfagna S. Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease. J Int Med Res 1984; 12: 286-291.